Skip to main content
. 2017 Jul 22;8(54):91860–91875. doi: 10.18632/oncotarget.19463

Figure 3. Combination of TLR1-10 significantly associates with overall survival for both NSCLC and ADC, specifically in stage 1 patients.

Figure 3

(A) Association between NSCLC patients and TLR1-10 mRNA expression (n= 1145) via multivariate analysis (co-variates: gender and histology); (B) Association between NSCLC patients that are only stage 1 and TLR1-10 mRNA expression (n=449) via multivariate analysis (co-variates: gender and histology); (C) Association between ADC patients and TLR1-10 mRNA expression (n=673) via multivariate analysis (co-variates: gender and stage); (D) Association between ADC patients that are only stage 1 and TLR1-10 mRNA expression (n=346) via univariate analysis. Analysis was performed using kmplot.com and Supplementary Table 1 has details for each of these analyses as well as stage 2 analyses. Hazard ratio (HR), 95% confidence intervals, and logrank P presented.